Dow Jones

38,587.13

-0.26%

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

PPBT

Purple Biotech (PPBT)

Purple Biotech Ltd

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:PPBT

1 2 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
03/06/2024	05:21	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PPBT	Purple Biotech Ltd
01/06/2024	07:00	GlobeNewswire Inc.	Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer	NASDAQ:PPBT	Purple Biotech Ltd
21/05/2024	06:30	GlobeNewswire Inc.	Purple Biotech Reports First Quarter 2024 Financial Results	NASDAQ:PPBT	Purple Biotech Ltd
25/04/2024	06:00	GlobeNewswire Inc.	Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	NASDAQ:PPBT	Purple Biotech Ltd
28/03/2024	06:00	GlobeNewswire Inc.	Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024	NASDAQ:PPBT	Purple Biotech Ltd
14/03/2024	06:30	GlobeNewswire Inc.	Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology	NASDAQ:PPBT	Purple Biotech Ltd
05/03/2024	15:00	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NASDAQ:PPBT	Purple Biotech Ltd
05/03/2024	06:55	GlobeNewswire Inc.	Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results	NASDAQ:PPBT	Purple Biotech Ltd
27/02/2024	06:00	GlobeNewswire Inc.	Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024	NASDAQ:PPBT	Purple Biotech Ltd
13/02/2024	06:00	GlobeNewswire Inc.	Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial	NASDAQ:PPBT	Purple Biotech Ltd
01/02/2024	06:30	GlobeNewswire Inc.	Purple Biotech Reaches Recommended Phase 2 Dose for NT219	NASDAQ:PPBT	Purple Biotech Ltd
20/12/2023	07:05	GlobeNewswire Inc.	Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors	NASDAQ:PPBT	Purple Biotech Ltd
14/12/2023	05:50	GlobeNewswire Inc.	Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	NASDAQ:PPBT	Purple Biotech Ltd
21/11/2023	05:50	GlobeNewswire Inc.	Purple Biotech Reports Third Quarter 2023 Financial Results	NASDAQ:PPBT	Purple Biotech Ltd
14/11/2023	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:PPBT	Purple Biotech Ltd
14/11/2023	15:13	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:PPBT	Purple Biotech Ltd
13/11/2023	15:11	Edgar (US Regulatory)	Form F-1/A - Registration statement for certain foreign private issuers: [Amend]	NASDAQ:PPBT	Purple Biotech Ltd
02/11/2023	06:00	GlobeNewswire Inc.	Purple Biotech Fortifies NT219 Patent Protection	NASDAQ:PPBT	Purple Biotech Ltd
31/10/2023	15:30	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:PPBT	Purple Biotech Ltd
30/10/2023	15:30	Edgar (US Regulatory)	Form F-1 - Registration statement for certain foreign private issuers	NASDAQ:PPBT	Purple Biotech Ltd
19/10/2023	14:55	GlobeNewswire Inc.	Purple Biotech Announces Closing of $5 Million Registered Direct Offering	NASDAQ:PPBT	Purple Biotech Ltd
19/10/2023	09:27	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:PPBT	Purple Biotech Ltd
17/10/2023	07:00	GlobeNewswire Inc.	Purple Biotech Announces $5 Million Registered Direct Offering	NASDAQ:PPBT	Purple Biotech Ltd
06/10/2023	06:50	GlobeNewswire Inc.	Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action	NASDAQ:PPBT	Purple Biotech Ltd
03/10/2023	06:50	GlobeNewswire Inc.	Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer	NASDAQ:PPBT	Purple Biotech Ltd
21/09/2023	07:00	GlobeNewswire Inc.	Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023	NASDAQ:PPBT	Purple Biotech Ltd
22/08/2023	08:29	GlobeNewswire Inc.	Purple Biotech Reports Second Quarter 2023 Financial Results	NASDAQ:PPBT	Purple Biotech Ltd
11/07/2023	07:15	GlobeNewswire Inc.	Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients	NASDAQ:PPBT	Purple Biotech Ltd
20/06/2023	07:01	Edgar (US Regulatory)	Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)	NASDAQ:PPBT	Purple Biotech Ltd
15/06/2023	15:01	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:PPBT	Purple Biotech Ltd